Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Imugene Advances Cancer Fight with 57% Complete Response Rate in CAR-T Trial
    • News

    Imugene Advances Cancer Fight with 57% Complete Response Rate in CAR-T Trial

    Industry Opportunity: Addressing a Critical Unmet Need The fight against blood cancer is evolving, and Imugene Limited (ASX:IMU) is at the forefront of this battle. With a new wave of promising results from its Phase 1b trial, Imugene’s allogeneic off-the-shelf CD19 CAR-T therapy, azer-cel, is demonstrating significant potential for patients with relapsed/refractory diffuse large B-cell

    Read More
    Public
  • MTM Unlocks Breakthrough in Gallium and Germanium Recovery
    • News

    MTM Unlocks Breakthrough in Gallium and Germanium Recovery

    A Game-Changer for Critical Metals Supply The global semiconductor and defence industries are facing a critical supply chain challenge, with key materials like gallium (Ga) and germanium (Ge) largely controlled by Chinese exports. MTM Critical Metals (ASX:MTM) has taken a major step towards addressing this issue, achieving high recovery rates of these metals from semiconductor

    Read More
    Public
  • Vinyl Group Expands Media Footprint with Launch of Vinyl Media
    • News

    Vinyl Group Expands Media Footprint with Launch of Vinyl Media

    Vinyl Group seizes cultural opportunity with premium publishing expansion Vinyl Group (ASX:VNL) is making bold moves in the Australian media landscape, unveiling a major rebrand and restructure of its media division as Vinyl Media. The company, Australia’s only ASX-listed music entity, is positioning itself as a powerhouse for cultural storytelling, blending premium publishing with audience

    Read More
    Public
  • Memphasys Reaches Key Milestone in Felix™ Clinical Trial, Data Lock Expected Soon
    • News

    Memphasys Reaches Key Milestone in Felix™ Clinical Trial, Data Lock Expected Soon

    Advanced Sperm Selection Technology Moves Closer to Market Memphasys Limited (ASX:MEM) has hit a critical milestone in its pivotal clinical trial for the Felix™ System, an innovative sperm selection technology designed for Assisted Reproductive Technology (ART) procedures. With the Last Patient Last Visit (LPLV) now completed, the company is entering the final phase before results

    Read More
    Public
  • Radiopharm’s RAD 101 Shows Promise in Detecting Brain Metastases
    • News

    Radiopharm’s RAD 101 Shows Promise in Detecting Brain Metastases

    New Imaging Breakthrough Targets Growing Brain Metastases Challenge Brain metastases are becoming increasingly prevalent due to improved cancer treatments extending patient survival. However, accurate detection remains a major clinical challenge. A new study highlights promising results for Radiopharm Theranostics’ (ASX:RAD, NASDAQ: RADX) novel imaging agent, RAD 101 (18F-Pivalate), in detecting brain metastases with high precision.

    Read More
    Public
  • Eureka Expands into All-Age Rental Market with Gladstone Acquisition
    • News

    Eureka Expands into All-Age Rental Market with Gladstone Acquisition

    Seizing an Opportunity in Affordable Rentals With home ownership in Australia becoming increasingly out of reach and rental demand surging, the all-age rental sector presents a significant growth opportunity. According to the most recent National Census, nearly 30% of Australians rent their homes, and 85% of these renters are under the age of 55. Eureka

    Read More
    Public
  • «
  • ‹
  • 21
  • 22
  • 23
  • 24
  • 25
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.